CMS is famous for not being able to negotiate prices – and its payment for physician-administered drugs notoriously incentivizes higher prices. Yet, as the Biogen/Eisai Aduhelm experience shows, CMS can on occasion have a profound impact on product launches when it chooses to.
At first glance, the reported sales for Biogen, Inc./Eisai Co., Ltd.’s newly launched Alzheimer’s treatment Aduhelm (aducanumab) looks like a typo: $300,000 in the third quarter.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.
No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.
The preliminary budget document supports legislation clawing back funds appropriated for the program.
Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.
The preliminary budget document supports legislation clawing back funds appropriated for the program.
Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.
